Cannabis Edibles for Tension Headache: The Most Common Headache Has No Cannabis Trial

Tension-type headache is the most common headache on the planet. The Global Burden of Disease team estimated that 1.89 billion people had it in 2016, almost double the 1.04 billion with migraine, and it is the headache most people mean when they type "cannabis for headaches" without the word migraine in front of it. It is also the headache cannabis research has skipped. There is no published controlled trial of cannabis, THC or CBD in tension-type headache, large or small, positive or negative.

So here is the position, stated early. For an ordinary tension headache, an edible is the wrong tool, slow to start, long to wear off, and untested against a headache the guidelines send to ibuprofen first. For people whose headaches come most days, the cannabis question worth asking is about rebound headache, and the answer there is not flattering. Our migraine page covers the headache with actual cannabis trials, and the cluster headache page covers the one where an edible is hopeless on timing alone.

Is there any research on cannabis for tension headaches?

Almost none. A 2026 systematic review that searched for double-blind cannabinoid trials in headache found two, one in migraine and one in medication-overuse headache, and concluded the evidence does not support a class-wide effect for headache disorders. The single registered tension-type trial, a CBD and CBN drink study in Poland, has not reported.

That Polish trial is the whole field. Wroclaw Medical University registered it as NCT05961501: 42 adults with facial pain and headache of muscular origin lasting more than three months, randomized to a daily CBD and CBN solution or placebo for 60 days, with completion estimated for December 2026. The record does not state the dose. Until it reports, every claim about cannabis for tension headache is borrowed from somewhere else.

The usual place it is borrowed from is Cuttler 2020 in the Journal of Pain, which analyzed 12,293 Strainprint app sessions where people inhaled cannabis for "headache" and found ratings dropped by roughly half. The app never asked what kind of headache, nobody was blinded, and the abstract adds that the effect appeared to shrink over time while the doses grew. Kuruvilla's 2025 review in Current Opinion in Neurology lands in the same spot: the retrospective studies look encouraging, and the missing controlled trials keep anyone from making a recommendation.

Does CBD help headaches?

In the only controlled headache trial with a CBD arm, it did not. Schuster's 2026 migraine trial gave vaporized CBD-dominant flower, THC-dominant flower, a mix, or placebo for four separate attacks, and the CBD-dominant flower did no better than placebo on any two-hour outcome. Nobody has run the equivalent test in tension-type headache.

The details make it worse for the CBD gummy. The 92 participants in that trial vaped 11% CBD flower, a faster route than any gummy, and it still did no better than placebo. The arms that won carried THC: the 6% THC flower beat placebo on pain relief (68.9% against 46.6%), and the THC plus CBD combination also beat it on pain freedom. That is migraine data, with a vaporizer, and it points to the THC. A hemp shop selling CBD gummies "for headaches" is selling the arm that lost.

Why does the timing work against an edible?

Because the edible is still loading while the headache runs its course. A standard edible takes 30 minutes to 2 hours to start and peaks 2 to 3 hours after eating, per our edible timing guide. ICHD-3 says a frequent episodic tension headache lasts from 30 minutes to 7 days, so the short ones are over first.

The long ones raise the opposite problem. The main effects of a standard edible run 4 to 8 hours, a long time to be impaired for a headache ICHD-3 calls mild to moderate and not worsened by climbing stairs. Fast-acting products shorten the wait on paper. Cann says its drinks have a typical onset of 10 to 15 minutes and can last two-plus hours, a brand claim that nobody has tested against a tension headache (our fast-acting edibles page explains why these formats start sooner).

Can cannabis cause rebound headaches?

Nobody has shown it in tension-type headache, and the migraine data point the wrong way. In a Stanford chart review of 368 chronic migraine patients, medication-overuse headache appeared in 81% of current cannabis users against 41% of non-users, an adjusted odds ratio of 6.3. That is an association in migraine patients, and it is the only one on record.

Medication-overuse headache, the condition people call rebound headache, has a precise definition in ICHD-3: headache on 15 or more days a month in someone with a pre-existing headache disorder, driven by regular overuse of acute headache medication for more than three months. The overuse line is 15 or more days a month for plain painkillers and 10 or more for triptans, opioids and combination pills. The ICHD-3 overuse criteria never name cannabis. Their catch-all code for medications not listed elsewhere, 8.2.8, sets the line at 10 days a month. ICHD-3 also notes that most people with medication-overuse headache started with migraine or tension-type headache.

The Stanford study (Zhang and Woldeamanuel, Headache, 2021) found cannabis use and opioid use travelling together, each linked to medication-overuse headache, which leaves open which came first. The authors still suggested that advising these patients to cut back on cannabis would help treat the overuse.

There is a counterweight, and it is small. Pini's 2012 trial in Modena took 30 people with long-standing medication-overuse headache, every one of whom had already tried detoxification at least three times without success, and gave them eight weeks of nabilone (a synthetic THC analogue) at 0.5mg a day and eight weeks of ibuprofen 400mg, in random order. Nabilone did better on pain intensity and daily painkiller intake. The number of headache days did not fall significantly. Twenty-six people finished, triptans were the overused drug in 53% of them, and nabilone is a prescription capsule, a long way from a dispensary gummy.

Can cannabis itself cause headaches?

Stopping it can. The 2022 clinical review of cannabis withdrawal in Addiction lists headaches among the less common physical symptoms, alongside chills, sweating and stomach pain, with onset 24 to 48 hours after the last use and most symptoms peaking on days 2 to 6. Our tolerance break guide covers that window from the other side.

The morning-after headache is harder to pin down. The one controlled "hangover" study, Chait 1985, had 13 men smoke 2.9% THC cigarettes or placebo in the evening and found changes on two subjective scales and a time-estimation task about nine hours later. Its abstract reports nothing about headache. A 2012 Turkish survey of 1,015 people in addiction treatment, 80.5% of them cannabis users, linked starting younger and using longer to more headache, and its authors warn that a single group with no comparison proves little. For the cannabis hangover headache, that is everything.

What do guidelines recommend for tension-type headache?

Simple painkillers for the episode and amitriptyline for chronic prevention. The European guideline (EFNS 2010), the VA/DoD guideline (2023) and NICE all start with aspirin, acetaminophen or an NSAID, the European guideline and NICE keep opioids out, and the European and VA/DoD documents name amitriptyline for chronic tension-type headache. None mentions cannabis.

The prevention drugs are no miracle either. A 2026 network meta-analysis of 35 trials ranked amitriptyline 100mg first for cutting monthly headache days in chronic tension-type headache, rated the evidence low to very low certainty, and found more side effects than placebo. That is still a trial record, which is more than any gummy has.

When does a headache need a doctor?

When it is new, sudden, worst-ever, changed, or comes with neurological symptoms. NICE lists sudden headache reaching full intensity within 5 minutes, new weakness or other neurological deficit, new confusion, fever, recent head trauma, and a substantial change in a person's usual headache. Headache on 15 or more days a month is its own reason.

The full NICE list adds headache triggered by coughing, sneezing or exercise, headache that changes with posture, and impaired consciousness, among others. The 15-day line comes from ICHD-3, where it marks both chronic tension-type headache and medication-overuse headache, and since more than half of people at that frequency have the overuse version, the first job is working out which one it is. A headache diary is the tool NICE and ICHD-3 both point to, and it costs nothing.

If someone buys a product anyway, what fits?

Two products from the same San Rafael delivery menu, priced on October 27, 2026, show the range. One is low-dose and makes a fast-onset claim. The other is a coffee bean, which is a strange thing to take for a headache.

The Cann is the closer fit for the timing problem, because 2mg of THC is a microdose and the brand's own onset claim is short. It is also priced like a cocktail and sold as a social drink, with no headache claim at all.

The Terra espresso bean is the honest critique. Kiva says the beans are micro-roasted Tanzanian coffee from Andytown Coffee Roasters, and its product page lists no caffeine figure. Caffeine is one of the better-documented headache variables there is. ICHD-3 counts it as an adjuvant in combination painkillers, which move the overuse line from 15 days to 10, and it has its own withdrawal headache, defined after more than 200mg a day for more than two weeks. A daily espresso-bean edible adds an unmeasured dose of the one ingredient a headache diary most needs to track. As a chocolate it is fine. As a headache product it is the wrong bean.